Pernicious and threatening plasmodium vivax as reality

American Journal of Tropical Medicine and Hygiene

Volumn 91, Issue 1, 2014, Pages 1-2

  Baird, J Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRIMAQUINE;

DISEASE SEVERITY; EDITORIAL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HIGH RISK POPULATION; MALARIA CONTROL; MEDICAL RESEARCH; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA;

ANEMIA; FEMALE; HOSPITALIZATION; HUMANS; LUNG INJURY; MALARIA, VIVAX; MALE; RENAL INSUFFICIENCY, CHRONIC; SHOCK;

EID: 84903896206     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0111     Document Type: Editorial

References (14)

1. Quispe AM, Pozo E, Guerrero E, Durand S, Baldeviano GC, Edgel KA, Graf PCF, Lescano AG, 2014. Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria? Am J Trop Med Hyg 91: 11-17.
2. Baird JK, 2013. Evidence and implication of mortality with acute Plasmodium vivax malaria. Clin Microbiol Rev 26: 36-57.
3. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN, 2012. Plasmodium vivax : clinical spectrum, risk factors and pathogenesis. Adv Parasitol 80: 151-201.
4. Church J, Maitland K, 2014. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review. BMC Med 12: 31.
5. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Mueller I, Baird JK, Hay SI, 2012. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 6: e1814.
6. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human parasite. Lancet Infect Dis 9: 555-566.
7. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685. (Pubitemid 30340814)
8. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57: 1128-1135.
9. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, 2011. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612-620.
10. McGready R, Lee SJ, Wiladphaningern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singhasivanon P, White NJ, Nosten FH, 2012. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12: 388-396.
11. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN, 2009. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 48: 1704-1712.
12. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, Sakuntabhai A, Satyagraha AW, Williams TN, Baird JK, Hay SI, 2013. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J 12: 418.
13. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 1381-1382.
14. Price RN, 2014. Editorial: improving the radical cure for Plasmodium vivax malaria. Am J Trop Med Hyg 91: 3-4.